Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for Prevention and Treatment of Radiation-Induced Xerostomia in Nasopharyngeal Carcinoma
ChiCTR2600127665Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Jiaxing University
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in nasopharyngeal carcinoma (NPC) and radiation-induced hyposalivation (RIX) comparing Experimental Group (Celecoxib) with Control Group (Placebo) (2 arms). Primary endpoint: Dry mouth severity. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
celecoxib
03
Conditions
nasopharyngeal carcinoma (NPC)radiation-induced hyposalivation (RIX)
Beyond the preview
Go deeper on ChiCTR2600127665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127665.